Rett Syndrome: Reaching for Clinical Trials

Academic Article

Abstract

  • © 2015, The American Society for Experimental NeuroTherapeutics, Inc. Rett syndrome (RTT) is a syndromic autism spectrum disorder caused by loss-of-function mutations in MECP2. The methyl CpG binding protein 2 binds methylcytosine and 5-hydroxymethycytosine at CpG sites in promoter regions of target genes, controlling their transcription by recruiting co-repressors and co-activators. Several preclinical studies in mouse models have identified rational molecular targets for drug therapies aimed at correcting the underlying neural dysfunction. These targeted therapies are increasingly translating into human clinical trials. In this review, we present an overview of RTT and describe the current state of preclinical studies in methyl CpG binding protein 2-based mouse models, as well as current clinical trials in individuals with RTT.
  • Published In

  • Neurotherapeutics  Journal
  • Digital Object Identifier (doi)

    Author List

  • Pozzo-Miller L; Pati S; Percy AK
  • Start Page

  • 631
  • End Page

  • 640
  • Volume

  • 12
  • Issue

  • 3